CYTOKINETICS INC (CYTK) 45.01 +0.45 (+1.01%)
45.01 +0.45 (+1.01%)
US23282W6057 - Common Stock - After market: 45.01 0 (0%)
Fundamental Rating
Overall CYTK gets a fundamental rating of 3 out of 10. We evaluated CYTK against 641 industry peers in the Biotechnology industry. CYTK scores bad on very profitability, while its financial health is fine. Not spectacular, but in line with the averages. CYTK shows excellent growth, but is valued quite expensive already.
Note: CYTK has only limited data available, so a full analysis was not possible, which makes the total rating unfair.
Profitability
Profitability Rating
The Piotroski-F score of CYTK is 3.00. This is a low score and indicates issues in the health and profitability of CYTK.
VS Industry
Valuation
Valuation Rating
CYTK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CYTK is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
VS Industry
Growth
Growth Rating
CYTK is expected to show a strong growth in Earnings Per Share. In the coming 5 years, the EPS will grow by 22.37% yearly.
CYTK shows a strong growth in Revenue. In the last year, the Revenue has grown by 587.85%.
CYTK is expected to show a strong growth in Revenue. In the coming 5 years, the Revenue will grow by 98.44% yearly.
The Revenue growth is accelerating: in the next 5 years the growth will be better than in the last years.
The earnings per share for CYTK have decreased by -1.29% in the last year.
Measured over the past 5 years, CYTK shows a decrease in Revenue. The Revenue has been decreasing by -7.92% on average per year.
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | N/A | N/A | -1.29% | -46.78% | -28.75% | -12.77% | 22.37% |
| Revenue | -7.92% | 30.76% | 587.85% | 367.47% | 66.08% | 86.06% | 98.44% |
Health
Health Rating
A Current Ratio of 11.56 indicates that CYTK has no problem at all paying its short term obligations.
The Current Ratio of CYTK is much better than the industry average of 6.18.
CYTK has a Quick Ratio of 11.56. This indicates that CYTK is financially healthy and has no problem in meeting its short term obligations.
CYTK is better placed than average in its industry to meet its short term obligations. Its Current Ratio is much better than the industry average of 6.05.
CYTK has a Altman-Z score comparable to the industry average, which is at -0.10.
CYTK has an Altman-Z score of 0.82. This is a bad value and indicates that CYTK is not financially healthy and even has some risk of bankruptcy.
CYTK has a quite weak Piotroski-F score of 3.00. This indicates issues in the health and profitability of CYTK.
VS Industry
Quick Ratio (11.56) VS Industry: 75% outperformed.
0.04
84.53
Current Ratio (11.56) VS Industry: 75% outperformed.
0.08
85.09
Altman-Z (0.82) VS Industry: 55% outperformed.
-2,801.75
658.20
Dividend
Dividend Rating
CYTK does not give a dividend.
CYTOKINETICS INC45.01
NASDAQ:CYTK (2/3/2023, 7:00:01 PM)+0.45 (+1.01%)
| GICS Sector | Health Care | ||
| GICS IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences | ||
| GICS Industry | Biotechnology | ||
| Earnings (Last) | 11-03 2022-11-03/amc | Earnings (Next) | 02-22 2023-02-22/amc |
| Inst Owners | 109.74% | Inst Owner Change | -0.15% |
| Ins Owners | 1.11% | Ins Owner Change | -1.08% |
| Market Cap | 4.26B | Analysts | 82.86 |
| Price Target | 63.31 (40.66%) | ||
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
| Dividend Growth(5Y) | N/A | DP | N/A |
| Div Incr Years | N/A | Div Non Decr Years | N/A |
| Ex-Date | N/A | ||
| EPS beat(2) | 1 | Avg EPS beat(2) | 25.28% |
| Min EPS beat(2) | -27.35% | Max EPS beat(2) | 77.91% |
| EPS beat(4) | 2 | Avg EPS beat(4) | 25.65% |
| Min EPS beat(4) | -27.35% | Max EPS beat(4) | 77.91% |
| Revenue beat(2) | 1 | Avg Revenue beat(2) | 1142.65% |
| Min Revenue beat(2) | -16.64% | Max Revenue beat(2) | 2301.94% |
| Revenue beat(4) | 2 | Avg Revenue beat(4) | 747.06% |
| Min Revenue beat(4) | -76.69% | Max Revenue beat(4) | 2301.94% |
| PT rev (1m) | -0.21% | PT rev (3m) | -8.84% |
| EPS NQ rev (1m) | 0% | EPS NQ rev (3m) | -5.84% |
| EPS NY rev (1m) | 0% | EPS NY rev (3m) | -14.09% |
| Revenue NQ rev (1m) | 0% | Revenue NQ rev (3m) | -10.47% |
| Revenue NY rev (1m) | 0% | Revenue NY rev (3m) | -2.13% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 28.73 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
| EPS(TTM) | -3.13 | EY | N/A |
| EPS(NY) | -4.69 | Fwd EY | N/A |
| FCF(TTM) | -2.87 | FCFY | N/A |
| OCF(TTM) | -2.6 | OCFY | N/A |
| SpS | 1.57 | BVpS | -0.17 |
| TBVpS | -0.17 | PEG (NY) | N/A |
| PEG (5Y) | N/A | ||
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM | N/A | ||
| GM | N/A |
| ROICexgc(3y) | N/A | ROICexcg growth 3Y | N/A |
| ROICexcg growth 5Y | N/A | ROICexc(3y) | N/A |
| ROICexc growth 3Y | N/A | ROICexc growth 5Y | N/A |
| OM growth 3Y | N/A | OM growth 5Y | N/A |
| PM growth 3Y | N/A | PM growth 5Y | N/A |
| GM growth 3Y | N/A | GM growth 5Y | N/A |
| F-Score | 3 | Asset Turnover | 0.14 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 529.33% | ||
| Profit Quality | N/A | ||
| Current Ratio | 11.56 | ||
| Quick Ratio | 11.56 | ||
| Altman-Z | 0.82 |
| F-Score | 3 | WACC | 9.05% |
| ROIC/WACC | N/A | Cap/Depr(3y) | 984.73% |
| Cap/Depr(5y) | 635.2% | Profit Quality(3y) | N/A |
| Profit Quality(5y) | N/A | ||
| EPS 1Y | -1.29% | EPS 3Y | N/A |
| EPS 5Y | N/A | EPS growth Q2Q | -60% |
| EPS Next Y | -46.78% | EPS Next 2Y | -28.75% |
| EPS Next 3Y | -12.77% | EPS Next 5Y | 22.37% |
| Revenue growth 1Y | 587.85% | Revenue growth 3Y | 30.76% |
| Revenue growth 5Y | -7.92% | Revenue growth Q2Q | -53.74% |
| Revenue Next Year | 367.47% | Revenue Next 2Y | 66.08% |
| Revenue Next 3Y | 86.06% | Revenue Next 5Y | 98.44% |
| EBIT growth 1Y | -8.88% | EBIT growth 3Y | N/A |
| EBIT growth 5Y | N/A | EBIT Next Year | -35.29% |
| EBIT Next 3Y | -21.85% | EBIT Next 5Y | 10.43% |
| FCF growth 1Y | -299.45% | FCF growth 3Y | N/A |
| FCF growth 5Y | N/A | OCF growth 1Y | -295.15% |
| OCF growth 3Y | N/A | OCF growth 5Y | N/A |
Fundamental Stock Screener Links
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Growth Stock Screener
Find more growth stocks the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA